Trends in prevalence of protective levels of hepatitis B surface antibody among adults aged 18-49 years with risk factors for hepatitis B virus infection-United States, 2003-2014.
Hepatitis B virus (HBV) infection can be prevented through vaccination; however previous data show that only about 24%-45% of U.S. adults at high risk of HBV infection are protected. Our aims were to assess prevalence and trends in protective levels of hepatitis B surface antibody from 2003-2014 and explore factors associated with protection among U.S. adults at high risk. Data were from the 2003-2014 National Health and Nutrition Examination Surveys. Our sample included adults, aged 18-49 years, who were tested for HBV and reported at least one of the following infection risks: history of STD, sex with men (for male respondents), infection with HIV, and injection drug use. We calculated the prevalence of hepatitis B surface antibody (anti-HBs, ≥10mIU/mL), indicative of immunity from vaccination among respondents for three 4-year time intervals (2003-2006, 2007-2010, and 2011-2014) and applied the Cochran-Mantel-Haenszel test to assess trends. Using multivariable logistic regression, we examined factors associated with positive anti-HBs serology. From 2003-2014, the prevalence of positive anti-HBs serology was 23.4%. Prevalence increased from 2003-2006 (16.3%) to 2007-2010 (27.3%), but no change occurred from 2007-2010 (27.3%) to 2011-2014 (28.1%). Among factors predicting positive anti-HBs serology were young age, female sex, and higher education. By 2014, less than one-third of adults, aged 18-49 years, at risk of infection exhibited anti-HBs ≥10 mIU/mL indicative of protection. Because these adults account for a substantial proportion of unprotected adults, targeted intervention strategies are essential to achieve the goal of hepatitis B elimination.